This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.
Source : Importé depuis le centre
RECRUTEMENT
Profil des participants
Limites d'âge
minimum : 18 ans
maximum : 70 ans
Sexe(s) des participants
ALL
Source : Importé depuis le centre
Condition médicale (spécialité visée)
Domaine de recherche
Donnée non disponible
Critères de sélection
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Alpha-1 MP 60 mg/kg
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Alpha-1 MP 120 mg/kg
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Placebo
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Alpha-1 MP 60 mg/kg
État du recrutement
unknown
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
Alpha-1 MP 120 mg/kg
État du recrutement
unknown
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
Placebo
État du recrutement
unknown
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
Données à jour depuis :
3 mars 2026
SITES ET CONTACTS
Centre principal
grifols investigative site
CHANDLER, ARIZONA, UNITED STATES
Recrutement local
—
FERMÉ
Aussi disponible à: VICENTE LÓPEZ, (BUENOS AIRES), CÓRDOBA, (CÓRDOBA PROVINCE), FORTITUDE VALLEY, (QUEENSLAND), SANTO ANDRÉ, (SÃO PAULO), SÃO PAULO, (SÃO PAULO), ST. JOHN'S, (NEWFOUNDLAND AND LABRADOR), HALIFAX, (NOVA SCOTIA), TORONTO, (ONTARIO), ARHUS C, HELLERUP, TALLINN, ...
et 26 autres villes.
Dernière modification :
3 mars 2026
Données à jour depuis :
5 mars
Origine des données :
clinicaltrials.gov
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles
Identifiant
GTI1201
Titre
Efficacy and safety of alpha1-proteinase inhibitor (human), modified process (alpha-1 mp) in subjects with pulmonary emphysema due to alpha1 antitrypsin deficiency (aatd)
* Have a documented total alpha1-PI serum level \< 11 µM.
* Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null), (null)(null), S(null), or "at-risk" alleles.
* At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30% and \< 80% of predicted and FEV1/forced vital capacity (FVC) \< 70% (Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] stage II or III).
* Have a carbon monoxide diffusing capacity (DLCO) ≤ 60% of predicted (corrected for HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the past 2 years per the Investigator's judgment.
* Have clinical evidence of pulmonary emphysema per the Investigator's judgment.
Exclusion Criteria:
* Has received alpha1-PI augmentation therapy for more than 1 month within the six months prior to the Screening Visit.
* Has received alpha1-PI augmentation therapy within one month of the Screening Visit.
* Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
* Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g., claustrophobic) undergo a CT scan.
* History of lung or liver transplant.
* Any lung surgery during the past 2 years (excluding lung biopsy).
* On the waiting list for lung surgery, including lung transplant.
* Smoking during the past 12 months or a positive urine cotinine test at screening that is due to smoking. Maybe on Nicotine replacement, including vapor cigarettes.
* History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
* Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e., 10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids are not considered systemic steroids) or during the Screening Phase.
* Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks prior to the Screening Visit or during the Screening Phase.
* Known selective or severe Immunoglobulin A (IgA) deficiency.
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Alpha-1 MP 60 mg/kg
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Alpha-1 MP 120 mg/kg
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Placebo
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
Donnée non disponible
Inconnu
Alpha-1 MP 60 mg/kg
État du recrutement
unknown
Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks
Alpha-1 MP 120 mg/kg
État du recrutement
unknown
Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks
Placebo
État du recrutement
unknown
0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks
Données à jour depuis :
3 mars 2026
Description de l'étude
Description de l'étude
Résumé de l'étude
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
10
affichés
sur
38
centres
GRIFOLS INVESTIGATIVE SITE
Vicente lópez
BUENOS AIRES, ARGENTINA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Córdoba
CÓRDOBA PROVINCE, ARGENTINA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Fortitude valley
QUEENSLAND, AUSTRALIA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Santo andré
SÃO PAULO, BRAZIL
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
São paulo
SÃO PAULO, BRAZIL
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
St. john's
NEWFOUNDLAND AND LABRADOR, CANADA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Halifax
NOVA SCOTIA, CANADA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Toronto
ONTARIO, CANADA
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Arhus c
DENMARK
Recrutement local
État du recrutement:
FERMÉ
GRIFOLS INVESTIGATIVE SITE
Chandler
ARIZONA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
Centres participants
Source d'information
Dernière modification :
3 mars 2026
Données à jour depuis :
5 mars
Origine des données :
clinicaltrials.gov